Correction to: When does chemical elaboration induce a ligand to change its binding mode? (Journal of Medicinal Chemistry (2017) 60:1 (128-145) DOI: 10.1021/acs.jmedchem.6b00725);When Does Chemical Elaboration Induce a Ligand To Change Its Binding Mode?

Journal of Medicinal Chemistry

Volumn 60, Issue 1, 2017, Pages 128-145

  Malhotra, Shipra ^a,b   Karanicolas, John ^a,b  

^a FOX CHASE CANCER CENTER   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAMASE INHIBITOR; INDOMETACIN; LIGAND; PROTEIN; RECEPTOR;

ARTICLE; BINDING AFFINITY; CHEMICAL ANALYSIS; CHEMICAL INTERACTION; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; IC50; LIGAND BINDING; PHYSICAL CHEMISTRY; PROTEIN STRUCTURE; SUBSTITUTION REACTION; CHEMICAL STRUCTURE; MOLECULAR MODEL; STRUCTURE ACTIVITY RELATION;

LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85018482636     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.7b00868     Document Type: Erratum

References (57)

1. Cumming, J. G.; Davis, A. M.; Muresan, S.; Haeberlein, M.; Chen, H. Chemical predictive modelling to improve compound quality Nat. Rev. Drug Discovery 2013, 12, 948-962 10.1038/nrd4128
2. Andersen, O. A.; Nathubhai, A.; Dixon, M. J.; Eggleston, I. M.; van Aalten, D. M. F. Structure-based dissection of the natural product cyclopentapeptide Chitinase inhibitor argifin Chem. Biol. 2008, 15, 295-301 10.1016/j.chembiol.2008.02.015
3. Stout, T. J.; Sage, C. R.; Stroud, R. M. The additivity of substrate fragments in enzyme-ligand binding Structure 1998, 6, 839-848 10.1016/S0969-2126(98)00086-0
4. Fry, D. C.; Wartchow, C.; Graves, B.; Janson, C.; Lukacs, C.; Kammlott, U.; Belunis, C.; Palme, S.; Klein, C.; Vu, B. Deconstruction of a Nutlin: dissecting the binding determinants of a potent protein-protein interaction inhibitor ACS Med. Chem. Lett. 2013, 4, 660-665 10.1021/ml400062c
5. Babaoglu, K.; Shoichet, B. K. Deconstructing fragment-based inhibitor discovery Nat. Chem. Biol. 2006, 2, 720-723 10.1038/nchembio831
6. Barelier, S.; Pons, J.; Marcillat, O.; Lancelin, J. M.; Krimm, I. Fragment-based deconstruction of Bcl-xL inhibitors J. Med. Chem. 2010, 53, 2577-2588 10.1021/jm100009z
7. Murray, C. W.; Verdonk, M. L.; Rees, D. C. Experiences in fragment-based drug discovery Trends Pharmacol. Sci. 2012, 33, 224-232 10.1016/j.tips.2012.02.006
8. Aguirre, C.; Brink, T. t.; Guichou, J.-F.; Cala, O.; Krimm, I. Comparing binding modes of analogous fragments using NMR in fragment-based drug design: application to PRDX5 PLoS One 2014, 9, e102300 10.1371/journal.pone.0102300
9. Murray, C. W.; Blundell, T. L. Structural biology in fragment-based drug design Curr. Opin. Struct. Biol. 2010, 20, 497-507 10.1016/j.sbi.2010.04.003
10. Zhang, Y.; Skolnick, J. TM-align: a protein structure alignment algorithm based on the TM-score Nucleic Acids Res. 2005, 33, 2302-2309 10.1093/nar/gki524
11. Rush, T. S., 3rd; Grant, J. A.; Mosyak, L.; Nicholls, A. A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction J. Med. Chem. 2005, 48, 1489-1495 10.1021/jm040163o
12. ROCS, version 3.2.0.3; OpenEye Scientific Software: Santa Fe, NM, 2015; http://www.eyesopen.com (accessed January 9, 2015).
13. Liebeschuetz, J.; Hennemann, J.; Olsson, T.; Groom, C. R. The good, the bad and the twisted: a survey of ligand geometry in protein crystal structures J. Comput.-Aided Mol. Des. 2012, 26, 169-183 10.1007/s10822-011-9538-6
14. Reynolds, C. H. Protein-ligand cocrystal structures: we can do better ACS Med. Chem. Lett. 2014, 5, 727-729 10.1021/ml500220a
15. Dauter, Z.; Wlodawer, A.; Minor, W.; Jaskolski, M.; Rupp, B. Avoidable errors in deposited macromolecular structures: an impediment to efficient data mining IUCrJ 2014, 1, 179-193 10.1107/S2052252514005442
16. Martin, D. P.; Cohen, S. M. Nucleophile recognition as an alternative inhibition mode for benzoic acid based carbonic anhydrase inhibitors Chem. Commun. 2012, 48, 5259-5261 10.1039/c2cc32013d
17. Innocenti, A.; Vullo, D.; Scozzafava, A.; Supuran, C. T. Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid Bioorg. Med. Chem. 2008, 16, 7424-7428 10.1016/j.bmc.2008.06.013
18. Waku, T.; Shiraki, T.; Oyama, T.; Maebara, K.; Nakamori, R.; Morikawa, K. The nuclear receptor PPARγ individually responds to serotonin-and fatty acid-metabolites EMBO J. 2010, 29, 3395-3407 10.1038/emboj.2010.197
19. Kalliokoski, T.; Kramer, C.; Vulpetti, A.; Gedeck, P. Comparability of mixed IC50 data - a statistical analysis PLoS One 2013, 8, e61007 10.1371/journal.pone.0061007
20. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 9997-10002 10.1073/pnas.96.18.9997
21. Du, J.-Q.; Wu, J.; Zhang, H.-J.; Zhang, Y.-H.; Qiu, B.-Y.; Wu, F.; Chen, Y.-H.; Li, J.-Y.; Nan, F.-J.; Ding, J.-P.; Li, J. Isoquinoline-1,3,4-trione derivatives inactivate caspase-3 by generation of reactive oxygen species J. Biol. Chem. 2008, 283, 30205-30215 10.1074/jbc.M803347200
22. Gowthaman, R.; Deeds, E. J.; Karanicolas, J. Structural properties of non-traditional drug targets present new challenges for virtual screening J. Chem. Inf. Model. 2013, 53, 2073-2081 10.1021/ci4002316
23. Houk, K. N.; Leach, A. G.; Kim, S. P.; Zhang, X. Binding affinities of host-guest, protein-ligand, and protein-transition-state complexes Angew. Chem., Int. Ed. 2003, 42, 4872-4897 10.1002/anie.200200565
24. Kozakov, D.; Hall, D. R.; Jehle, S.; Luo, L.; Ochiana, S. O.; Jones, E. V.; Pollastri, M.; Allen, K. N.; Whitty, A.; Vajda, S. Ligand deconstruction: Why some fragment binding positions are conserved and others are not Proc. Natl. Acad. Sci. U. S. A. 2015, 112, E2585-E2594 10.1073/pnas.1501567112
25. Kozakov, D.; Grove, L. E.; Hall, D. R.; Bohnuud, T.; Mottarella, S. E.; Luo, L.; Xia, B.; Beglov, D.; Vajda, S. The FTMap family of web servers for determining and characterizing ligand-binding hot spots of proteins Nat. Protoc. 2015, 10, 733-755 10.1038/nprot.2015.043
26. Hussein, H. A.; Borrel, A.; Geneix, C.; Petitjean, M.; Regad, L.; Camproux, A. C. PockDrug-Server: a new web server for predicting pocket druggability on holo and apo proteins Nucleic Acids Res. 2015, 43, W436-442 10.1093/nar/gkv462
27. Borrel, A.; Regad, L.; Xhaard, H.; Petitjean, M.; Camproux, A. C. PockDrug: A model for predicting pocket druggability that overcomes pocket estimation uncertainties J. Chem. Inf. Model. 2015, 55, 882-895 10.1021/ci5006004
28. Cox, D. R. The regression analysis of binary sequences J. R. Statist. Soc. B 1958, 20, 215-242
29. Nair, S. K.; Ludwig, P. A.; Christianson, D. W. Two-site binding of phenol in the active site of human carbonic anhydrase II: Structural implications for substrate association J. Am. Chem. Soc. 1994, 116, 3659-3660 10.1021/ja00087a086
30. Davies, D. R.; Mamat, B.; Magnusson, O. T.; Christensen, J.; Haraldsson, M. H.; Mishra, R.; Pease, B.; Hansen, E.; Singh, J.; Zembower, D.; Kim, H.; Kiselyov, A. S.; Burgin, A. B.; Gurney, M. E.; Stewart, L. J. Discovery of leukotriene A4 hydrolase inhibitors using metabolomics biased fragment crystallography J. Med. Chem. 2009, 52, 4694-4715 10.1021/jm900259h
31. Manos-Turvey, A.; Bulloch, E. M.; Rutledge, P. J.; Baker, E. N.; Lott, J. S.; Payne, R. J. Inhibition studies of Mycobacterium tuberculosis salicylate synthase (MbtI) ChemMedChem 2010, 5, 1067-1079 10.1002/cmdc.201000137
32. Chi, G.; Manos-Turvey, A.; O’Connor, P. D.; Johnston, J. M.; Evans, G. L.; Baker, E. N.; Payne, R. J.; Lott, J. S.; Bulloch, E. M. Implications of binding mode and active site flexibility for inhibitor potency against the salicylate synthase from Mycobacterium tuberculosis Biochemistry 2012, 51, 4868-4879 10.1021/bi3002067
33. Jiang, L.-G.; Yu, H.-Y.; Yuan, C.; Wang, J.-D.; Chen, L.-Q.; Meehan, E. J.; Huang, Z.-X.; Huang, M.-D. Crystal structures of 2-aminobenzothiazole-based inhibitors in complexes with urokinase-type plasminogen activator Chin. J. Struct. Chem. 2009, 28, 1427-1432
34. Fischmann, T. O.; Hruza, A.; Duca, J. S.; Ramanathan, L.; Mayhood, T.; Windsor, W. T.; Le, H. V.; Guzi, T. J.; Dwyer, M. P.; Paruch, K.; Doll, R. J.; Lees, E.; Parry, D.; Seghezzi, W.; Madison, V. Structure-guided discovery of cyclin-dependent kinase inhibitors Biopolymers 2008, 89, 372-379 10.1002/bip.20868
35. Zartler, E. R. Fragonomics: the-omics with real impact ACS Med. Chem. Lett. 2014, 5, 952-953 10.1021/ml5003212
36. Murray, C. W.; Rees, D. C. The rise of fragment-based drug discovery Nat. Chem. 2009, 1, 187-192 10.1038/nchem.217
37. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A ‘rule of three’ for fragment-based lead discovery? Drug Discovery Today 2003, 8, 876-877 10.1016/S1359-6446(03)02831-9
38. Jhoti, H.; Williams, G.; Rees, D. C.; Murray, C. W. The ’rule of three’ for fragment-based drug discovery: where are we now? Nat. Rev. Drug Discovery 2013, 12, 644-644 10.1038/nrd3926-c1
39. Murray, C. W.; Carr, M. G.; Callaghan, O.; Chessari, G.; Congreve, M.; Cowan, S.; Coyle, J. E.; Downham, R.; Figueroa, E.; Frederickson, M.; Graham, B.; McMenamin, R.; O’Brien, M. A.; Patel, S.; Phillips, T. R.; Williams, G.; Woodhead, A. J.; Woolford, A. J. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency J. Med. Chem. 2010, 53, 5942-5955 10.1021/jm100059d
40. Bussenius, J.; Blazey, C. M.; Aay, N.; Anand, N. K.; Arcalas, A.; Baik, T.; Bowles, O. J.; Buhr, C. A.; Costanzo, S.; Curtis, J. K.; DeFina, S. C.; Dubenko, L.; Heuer, T. S.; Huang, P.; Jaeger, C.; Joshi, A.; Kennedy, A. R.; Kim, A. I.; Lara, K.; Lee, J.; Li, J.; Lougheed, J. C.; Ma, S.; Malek, S.; Manalo, J. C.; Martini, J. F.; McGrath, G.; Nicoll, M.; Nuss, J. M.; Pack, M.; Peto, C. J.; Tsang, T. H.; Wang, L.; Womble, S. W.; Yakes, M.; Zhang, W.; Rice, K. D. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90 Bioorg. Med. Chem. Lett. 2012, 22, 5396-5404 10.1016/j.bmcl.2012.07.052
41. Aguirre, C.; ten Brink, T.; Guichou, J. F.; Cala, O.; Krimm, I. Comparing binding modes of analogous fragments using NMR in fragment-based drug design: application to PRDX5 PLoS One 2014, 9, e102300 10.1371/journal.pone.0102300
42. Czodrowski, P.; Holzemann, G.; Barnickel, G.; Greiner, H.; Musil, D. Selection of fragments for kinase inhibitor design: decoration is key J. Med. Chem. 2015, 58, 457-465 10.1021/jm501597j
43. Brough, P. A.; Barril, X.; Borgognoni, J.; Chene, P.; Davies, N. G. M.; Davis, B.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Garcia-Echeverria, C.; Fromont, C.; Hayes, A.; Hubbard, R. E.; Jordan, A. M.; Jensen, M. R.; Massey, A.; Merrett, A.; Padfield, A.; Parsons, R.; Radimerski, T.; Raynaud, F. I.; Robertson, A.; Roughley, S. D.; Schoepfer, J.; Simmonite, H.; Sharp, S. Y.; Surgenor, A.; Valenti, M.; Walls, S.; Webb, P.; Wood, M.; Workman, P.; Wright, L. Combining hit identification strategies: Fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone J. Med. Chem. 2009, 52, 4794-4809 10.1021/jm900357y
44. Wang, R.; Fang, X.; Lu, Y.; Wang, S. The PDBbind database: Collection of binding affinities for protein-ligand complexes with known three-dimensional structures J. Med. Chem. 2004, 47, 2977-2980 10.1021/jm030580l
45. Liu, Z.; Li, Y.; Han, L.; Li, J.; Liu, J.; Zhao, Z.; Nie, W.; Liu, Y.; Wang, R. PDB-wide collection of binding data: current status of the PDBbind database Bioinformatics 2015, 31, 405-412 10.1093/bioinformatics/btu626
46. UniProt: a hub for protein information. Nucleic Acids Res. 2015, 43, D204-D212; DOI: 10.1093/nar/gku989.
47. O’Boyle, N.; Banck, M.; James, C.; Morley, C.; Vandermeersch, T.; Hutchison, G. Open Babel: An open chemical toolbox J. Cheminf. 2011, 3, 33 10.1186/1758-2946-3-33
48. Englert, P.; Kovacs, P. Efficient heuristics for maximum common substructure search J. Chem. Inf. Model. 2015, 55, 941-955 10.1021/acs.jcim.5b00036
49. Kleywegt, G. J.; Harris, M. R.; Zou, J.-y.; Taylor, T. C.; Wahlby, A.; Jones, T. A. The Uppsala Electron-Density server Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2240-2249 10.1107/S0907444904013253
50. The PyMOL Molecular Graphics System, version 1.8; Schrödinger, LLC.
51. Bietz, S.; Urbaczek, S.; Schulz, B.; Rarey, M. Protoss: a holistic approach to predict tautomers and protonation states in protein-ligand complexes J. Cheminf. 2014, 6, 12 10.1186/1758-2946-6-12
52. Hawkins, P. C. D.; Skillman, A. G.; Warren, G. L.; Ellingson, B. A.; Stahl, M. T. Conformer generation with OMEGA: Algorithm and validation using high quality structures from the Protein Databank and Cambridge Structural Database J. Chem. Inf. Model. 2010, 50, 572-584 10.1021/ci100031x
53. Hawkins, P. C.; Nicholls, A. Conformer generation with OMEGA: learning from the data set and the analysis of failures J. Chem. Inf. Model. 2012, 52, 2919-2936 10.1021/ci300314k
54. OMEGA, version 2.4.3; OpenEye Scientific Software: Santa Fe, NM, 2015; http://www.eyesopen.com (accessed January 9, 2015).
55. Leaver-Fay, A.; Tyka, M.; Lewis, S. M.; Lange, O. F.; Thompson, J.; Jacak, R.; Kaufman, K. W.; Renfrew, P. D.; Smith, C. A.; Sheffler, W.; Davis, I. W.; Cooper, S.; Treuille, A.; Mandell, D. J.; Richter, F.; Ban, Y.-E. A.; Fleishman, S. J.; Corn, J. E.; Kim, D. E.; Lyskov, S.; Berrondo, M.; Mentzer, S.; Popović, Z.; Havranek, J. J.; Karanicolas, J.; Das, R.; Meiler, J.; Kortemme, T.; Gray, J. J.; Kuhlman, B.; Baker, D.; Bradley, P. Rosetta3: An object-oriented software suite for the simulation and design of macromolecules Methods Enzymol. 2011, 487, 545-574 10.1016/B978-0-12-381270-4.00019-6
56. Feig, M.; Karanicolas, J.; Brooks, C. L., III MMTSB Tool Set: enhanced sampling and multiscale modeling methods for applications in structural biology J. Mol. Graphics Modell. 2004, 22, 377-395 10.1016/j.jmgm.2003.12.005
57. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2010.